Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 3.84
RGLS's Cash-to-Debt is ranked lower than
64% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. RGLS: 3.84 )
Ranked among companies with meaningful Cash-to-Debt only.
RGLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.81  Med: 9.68 Max: No Debt
Current: 3.84
Equity-to-Asset 0.56
RGLS's Equity-to-Asset is ranked lower than
61% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. RGLS: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
RGLS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.97  Med: 0.68 Max: 0.88
Current: 0.56
-0.97
0.88
Piotroski F-Score: 1
Altman Z-Score: -4.63
Beneish M-Score: -6.17
WACC vs ROIC
20.42%
-3020.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -6825.88
RGLS's Operating Margin % is ranked lower than
90% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. RGLS: -6825.88 )
Ranked among companies with meaningful Operating Margin % only.
RGLS' s Operating Margin % Range Over the Past 10 Years
Min: -6825.96  Med: -180.19 Max: -51.76
Current: -6825.88
-6825.96
-51.76
Net Margin % -6853.94
RGLS's Net Margin % is ranked lower than
91% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. RGLS: -6853.94 )
Ranked among companies with meaningful Net Margin % only.
RGLS' s Net Margin % Range Over the Past 10 Years
Min: -6853.94  Med: -180.9 Max: -55.13
Current: -6853.94
-6853.94
-55.13
ROE % -91.23
RGLS's ROE % is ranked lower than
76% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. RGLS: -91.23 )
Ranked among companies with meaningful ROE % only.
RGLS' s ROE % Range Over the Past 10 Years
Min: -169.02  Med: -50.28 Max: -24
Current: -91.23
-169.02
-24
ROA % -66.42
RGLS's ROA % is ranked lower than
74% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. RGLS: -66.42 )
Ranked among companies with meaningful ROA % only.
RGLS' s ROA % Range Over the Past 10 Years
Min: -67.7  Med: -35.57 Max: -16.48
Current: -66.42
-67.7
-16.48
ROC (Joel Greenblatt) % -670.89
RGLS's ROC (Joel Greenblatt) % is ranked lower than
54% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. RGLS: -670.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RGLS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1544.17  Med: -592.79 Max: -450.68
Current: -670.89
-1544.17
-450.68
3-Year Revenue Growth Rate -64.40
RGLS's 3-Year Revenue Growth Rate is ranked lower than
87% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. RGLS: -64.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RGLS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -77 Max: -36.1
Current: -64.4
3-Year EBITDA Growth Rate 49.00
RGLS's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. RGLS: 49.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RGLS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.25 Max: 49
Current: 49
0
49
3-Year EPS without NRI Growth Rate 46.80
RGLS's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. RGLS: 46.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RGLS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -47.7 Max: 46.8
Current: 46.8
0
46.8
GuruFocus has detected 4 Warning Signs with Regulus Therapeutics Inc $RGLS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RGLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
Q3 2015

RGLS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q3 2016

RGLS Guru Trades in Q3 2016

Jim Simons 645,000 sh (New)
» More
Q4 2016

RGLS Guru Trades in Q4 2016

Paul Tudor Jones 46,688 sh (New)
Jim Simons 321,200 sh (-50.20%)
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BLRX, OTCPK:THCBF, NAS:AVEO, OTCPK:CNNRF, NAS:CAPR, NAS:CUR, NAS:ADMA, OTCPK:CAIHF, NAS:TCON, AMEX:CRMD, NAS:IPCI, OTCPK:AMEUF, NAS:GLMD, NAS:KMPH, NAS:MTFB, NAS:BUR, NAS:GTXI, OTCPK:CWBR, NAS:DRNA, NAS:FLKS » details
Traded in other countries:7RG.Germany,
Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing drugs that target micro RNAs to treat various diseases.

Regulus Therapeutics is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Ratios

vs
industry
vs
history
PB Ratio 1.33
RGLS's PB Ratio is ranked higher than
87% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. RGLS: 1.33 )
Ranked among companies with meaningful PB Ratio only.
RGLS' s PB Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.57 Max: 12.95
Current: 1.33
1.04
12.95
PS Ratio 63.64
RGLS's PS Ratio is ranked lower than
76% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. RGLS: 63.64 )
Ranked among companies with meaningful PS Ratio only.
RGLS' s PS Ratio Range Over the Past 10 Years
Min: 0.1  Med: 19.6 Max: 115.91
Current: 63.64
0.1
115.91
Current Ratio 6.34
RGLS's Current Ratio is ranked higher than
66% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. RGLS: 6.34 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s Current Ratio Range Over the Past 10 Years
Min: 3.01  Med: 7.05 Max: 11.3
Current: 6.34
3.01
11.3
Quick Ratio 5.93
RGLS's Quick Ratio is ranked higher than
65% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. RGLS: 5.93 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s Quick Ratio Range Over the Past 10 Years
Min: 3.01  Med: 6.84 Max: 11.3
Current: 5.93
3.01
11.3
Days Sales Outstanding 506.54
RGLS's Days Sales Outstanding is ranked lower than
98% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. RGLS: 506.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.47  Med: 94.62 Max: 506.54
Current: 506.54
1.47
506.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.20
RGLS's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. RGLS: -8.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RGLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -719.3  Med: -10.95 Max: 0
Current: -8.2
-719.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.33
RGLS's Price-to-Net-Cash is ranked higher than
84% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. RGLS: 2.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RGLS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.92  Med: 3.99 Max: 6.52
Current: 2.33
1.92
6.52
Price-to-Net-Current-Asset-Value 1.73
RGLS's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. RGLS: 1.73 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RGLS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.42  Med: 3.91 Max: 6.27
Current: 1.73
1.42
6.27
Price-to-Tangible-Book 1.35
RGLS's Price-to-Tangible-Book is ranked higher than
89% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. RGLS: 1.35 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RGLS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.11  Med: 3.7 Max: 6
Current: 1.35
1.11
6
Price-to-Median-PS-Value 3.26
RGLS's Price-to-Median-PS-Value is ranked lower than
88% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. RGLS: 3.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RGLS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1.1 Max: 5.23
Current: 3.26
0.01
5.23
Earnings Yield (Greenblatt) % -467.01
RGLS's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. RGLS: -467.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RGLS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1813.33  Med: 39.35 Max: 44.4
Current: -467.01
-1813.33
44.4

More Statistics

Revenue (TTM) (Mil) $1.19
EPS (TTM) $ -1.55
Beta2.55
Short Percentage of Float6.46%
52-Week Range $0.94 - 8.90
Shares Outstanding (Mil)52.93

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 0 0 0
EPS ($) -1.05 -1.10 -1.27
EPS without NRI ($) -1.05 -1.10 -1.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RGLS

Headlines

Articles On GuruFocus.com
Top Insider Buys, Sells of the Week Feb 26 2016 
Weekly CEO Sells Highlight: Hovnanian Enterprises Inc, Regulus Therapeutics Inc, Monster Beverage Co Apr 27 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
This Week’s Pharma Highlights Mar 19 2015 
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe S Feb 01 2015 

More From Other Websites
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on... Mar 24 2017
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Mar 24 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 24 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics... Mar 22 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf... Mar 22 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Mar 20 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 20 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Mar 17 2017
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Mar 17 2017
RGLS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 17 2017
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Mar 15 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 15 2017
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus... Mar 14 2017
RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action... Mar 13 2017
IMPORTANT ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus... Mar 09 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 09 2017
REGULUS THERAPEUTICS INC. Financials Mar 08 2017
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against... Mar 08 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on... Mar 08 2017
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And... Mar 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)